首页> 外文期刊>Reviews in cardiovascular medicine >Society for cardiovascular magnetic resonance: Advances in research and clinical applications - Highlights from the 13th Annual SCMR Scientific Sessions, January 21-24, 2010, Phoenix, AZ
【24h】

Society for cardiovascular magnetic resonance: Advances in research and clinical applications - Highlights from the 13th Annual SCMR Scientific Sessions, January 21-24, 2010, Phoenix, AZ

机译:心血管磁共振学会:研究和临床应用的进展-2010年1月21日至24日,亚利桑那州凤凰城,第13届SCMR年度科学会议摘要

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: This study evaluates the efficiency of prophylactic tranexamic acid in coronary bypass surgery with respect to preoperative clopidogrel use. Methods: We analyzed data for 3754 consecutive patients who underwent isolated coronary bypass surgery with cardiopulmonary bypass between January 1999 and August 2008. The patients were placed into 4 groups according to the perioperative use of clopidogrel and tranexamic acid. Group 1 included patients administered neither of these medications (n = 3160, 84.2%); group 2 included patients who received tranexamic acid only (n = 444, 11.8%); group 3 included patients who received clopidogrel only (n = 113, 3.0%); and group 4 included patients who received both medications (n = 37, 1.0%). Results: In patients who received tranexamic acid, we noted significant decreases in postoperative drainage (615 ± 336 mL versus 458 ± 289 mL, group 1 versus group 2 [P = .0001]; 740 ± 399 mL versus 570 ± 408 mL, group 3 versus group 4 [P = .03]) and the use of fresh frozen plasma (1.4 ± 1.4 units/patient versus 0.2 ± 0.7 units/patient, group 1 versus group 2 [P = .0001]; 2.2 ± 1.7 units/patient versus 0.5 ± 1.3 units/patient, group 3 versus group 4 [P = .0001]), irrespective of the use of clopidogrel. We found significant decreases in postoperative blood transfusion (0.59 ± 1.1 units/ patient versus 0.39 ± 1.1 units/patient, group 1 versus group 2 [P = .0001]; 1.2 ± 1.8 units/patient versus 0.7 ± 1.1 units/ patient, group 3 versus group 4 [P > .05]) and in the percentage of patients who received transfusions (31.3% versus 19.3%, group 1 versus group 2 [P = .0001]; 54.5% versus 37.8%, group 3 versus group 4 [P > .05]) only in the patients who did not receive clopidogrel. Conclusion: Prophylactic tranexamic acid reduces bleeding and the need for transfusion. This effect exists in patients using clopidogrel but is less prominent. Preoperative use may be beneficial in patients using clopidogrel without any need for delaying the surgical procedure.
机译:目的:本研究评估了预防性氨甲环酸在冠状动脉搭桥手术中与术前使用氯吡格雷有关的效率。方法:我们分析了1999年1月至2008年8月间连续3754例行体外循环体外循环冠状动脉搭桥手术的患者的数据。根据围手术期使用氯吡格雷和氨甲环酸的方法将患者分为4组。第一组包括既不接受上述药物治疗的患者(n = 3160,84.2%);第2组包括仅接受氨甲环酸的患者(n = 444,11.8%);第3组包括仅接受氯吡格雷的患者(n = 113,3.0%);第4组包括接受过两种药物治疗的患者(n = 37,1.0%)。结果:在接受氨甲环酸的患者中,我们注意到术后引流显着减少(第1组与第2组相比,615±336 mL对458±289 mL,[P = .0001];与第570±408 mL组相比,740±399 mL) 3与4组比较[P = .03]和使用新鲜冷冻血浆(1.4±1.4单位/患者vs 0.2±0.7单位/患者,1组与2组比较[P = .0001]; 2.2±1.7单位/患者与0.5±1.3单位/患者,第3组对第4组的比较[P = .0001],而与使用氯吡格雷无关。我们发现术后输血显着减少(0.59±1.1单位/患者与0.39±1.1单位/患者,第1组与第2组[P = .0001]; 1.2±1.8单位/患者与0.7±1.1单位/患者,组3与第4组比较[P> .05]和接受输血的患者百分比(31.3%对19.3%,第1组与第2组比较[P = .0001]; 54.5%对37.8%,第3组对第4组[P> .05])仅在未接受氯吡格雷的患者中使用。结论:预防性氨甲环酸可减少出血和输血需求。使用氯吡格雷的患者存在这种作用,但效果较差。术前使用对使用氯吡格雷的患者可能有益,而无需延迟手术过程。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号